2.07 USD
+0.14 (+7.25%)
2.12 USD
+0.05 (+2.42%)
IPA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. IPA has a bad profitability rating. Also its financial health evaluation is rather negative. IPA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IPA had negative earnings in the past year.
In the past year IPA has reported a negative cash flow from operations.
In the past 5 years IPA always reported negative net income.
In the past 5 years IPA always reported negative operating cash flow.
1.2 Ratios
IPA's Return On Assets of -68.03% is on the low side compared to the rest of the industry. IPA is outperformed by 89.09% of its industry peers.
IPA has a worse Return On Equity (-127.97%) than 83.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROIC | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 55.25%, IPA is doing good in the industry, outperforming 65.45% of the companies in the same industry.
IPA's Gross Margin has been stable in the last couple of years.
IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IPA has been increased compared to 5 years ago.
Compared to 1 year ago, IPA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.35, we must say that IPA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.35, IPA is not doing good in the industry: 76.36% of the companies in the same industry are doing better.
IPA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
IPA has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: IPA underperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACCN/A
WACC10.11%
2.3 Liquidity
A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
The Current ratio of IPA (2.08) is comparable to the rest of the industry.
A Quick Ratio of 1.85 indicates that IPA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.85, IPA perfoms like the industry average, outperforming 47.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.78% over the past year.
The Revenue has been growing slightly by 0.01% in the past year.
IPA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.77% yearly.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
3.2 Future
The Earnings Per Share is expected to grow by 39.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.92% on average over the next years. This is quite good.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IPA's earnings are expected to grow with 35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%
5. Dividend
5.1 Amount
IPA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.07
+0.14 (+7.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners8.61%
Inst Owner Change2.3%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Revenue(TTM)24.52M
Net Income(TTM)-30.23M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.6 | ||
| P/tB | 9.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% | ||
| FCFM | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.61% | ||
| Cap/Sales | 3.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z | -0.35 |
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IPA.
Can you provide the valuation status for IMMUNOPRECISE ANTIBODIES LTD?
ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.
What is the profitability of IPA stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.
Can you provide the financial health for IPA stock?
The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.
Can you provide the expected EPS growth for IPA stock?
The Earnings per Share (EPS) of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 49.5% in the next year.